HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

Access earnings results, analyst expectations, report, slides, earnings call, and transcript.

Overview

HeartFlow's Q1 2026 earnings call reveals strong financial performance with a 20% revenue increase, improved gross margins, and a turnaround to net income. Despite lacking specific future guidance, the positive growth in revenue and profitability, combined with increased cash flow, indicates a healthy financial trajectory. The strategic focus on R&D and market expansion further supports positive sentiment. The absence of significant negative indicators or analyst concerns in the Q&A reinforces a positive outlook for the stock price over the next two weeks.

Key Financial Performance

Revenue HeartFlow reported a revenue of $45 million for Q1 2026, representing a 20% increase year-over-year. This growth was driven by strong demand for its non-invasive coronary artery disease diagnostic solutions and expanded customer base.

Gross Margin The gross margin for Q1 2026 was 75%, up from 72% in Q1 2025. The improvement was attributed to operational efficiencies and cost management initiatives.

Operating Expenses Operating expenses for Q1 2026 were $30 million, a 15% increase compared to Q1 2025. The rise was due to increased investments in R&D and sales and marketing efforts to support growth.

Net Income Net income for Q1 2026 was $5 million, compared to a net loss of $2 million in Q1 2025. This turnaround was driven by higher revenue and improved gross margins.

Cash Flow Cash flow from operations was $10 million in Q1 2026, up from $6 million in Q1 2025. The increase was due to improved profitability and efficient working capital management.

You have reached the limit. Sign up to access full content

Get started

Operating Highlights

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Risk or Challenges

Forward-looking statements: The company's forward-looking statements involve risks and uncertainties, which could lead to actual results differing materially from expectations.

You have reached the limit. Sign up to access full content

Get started

Guidance & Outlook

Commercial Momentum: Updates on commercial momentum were discussed, but specific future-oriented details were not provided.

Innovation Pipeline: Updates on the innovation pipeline were discussed, but specific future-oriented details were not provided.

Clinical Programs: Updates on clinical programs were discussed, but specific future-oriented details were not provided.

Financial Guidance: Financial guidance will be provided during the call.

You have reached the limit. Sign up to access full content

Get started

Shareholder Return Plan

The selected topic was not discussed during the call.

You have reached the limit. Sign up to access full content

Get started

Key Q&A

Q:Review of Unclear Management Responses

You have reached the limit. Sign up to access full content

Get started

Earnings Word Cloud

The most frequently occurring keywords in this quarter's earning call

HTFL Transcript

HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

Positive5-14

HeartFlow, Inc. (HTFL) Q4 2025 Earnings Call Transcript

Positive3-18

The earnings call summary reflects strong U.S. revenue growth, improved operating leverage, and reduced losses. Management expressed high confidence in future guidance, driven by product adoption and competitive advantages. The Q&A section revealed positive sentiment towards growth drivers and strategic innovations. However, there was some avoidance of direct answers regarding Q1 consensus revenue, which slightly tempers the overall positive sentiment. The solid cash position supports continued investment, and the outlook for shareholder returns remains favorable, contributing to a positive stock price prediction.

HeartFlow, Inc. (HTFL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Neutral1-13

Frequently Asked Questions

Where does this earnings call transcript come from?

All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.

How soon is the transcript available after the earnings call ends?

Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.

Is the transcript edited or altered in any way?

No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.

Why do some answers appear as “Unclear” or “Inaudible”?

When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.

Who creates the AI Summary and Key Q&A highlights shown above the transcript?

They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.